ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LNTH / news
ORKA (53) NEOG (47) CLDX (29) NTLA (25) ⌘ Pro Terminal →

Why LNTH Stock slipped -0.15% Today — RQD Quant Desk Flash

$100.31 -0.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $100.52

Lantheus Holdings Inc. (LNTH) earns a Roarable Rating of B+ (Buy) with 76/100 RQD Confidence. High-quality cash engine (61.1% gross margin, 20% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $6.55B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LNTH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LNTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Lantheus Holdings Inc. (NASDAQ: LNTH) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $100.31 (-0.15% 1D, market cap $6.55B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, LNTH ranks #29 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LNTH compare to ORKA and NEOG in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), LNTH carries a Roarable B+ (76/100 RQD), trailing P/E of 28.0x, gross margin of 61.1%, and ROIC of 20.3%. By comparison, ORKA (Oruka Therapeutics Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -18.8%, cap $6.32B) and NEOG (Neogen Corporation) posts a D grade (47/100 RQD, P/E N/A, ROIC -0.6%, cap $2.58B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LNTH?
▼

Per LNTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001521036), Lantheus Holdings Inc. generated $1.54B in revenue (+0.5% YoY), $233.6M in net income, and $320.8M in free cash flow against $2.23B in total assets and $511.9M in total debt. Key quantitative strengths: Strong cash generator (61.1% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $100.52 (+0.21%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 20.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B+
025507510076
3-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B+ · Rk B
Cash (17)Whales (15)SEC (15)Macro (14)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+8.1% Base Target
$128 Bull$108 Base$82 Bear
📬 FREE LNTH RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LNTH)Realized 20D OHLCV Swing Band: ±1.8%
Deterministic 5-Pillar Attribution (76/100 Composite)
🔍 WHY LNTH SCORES 76/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 20.8% FCF Margin ($320.8M FCF) & 61.1% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+15/20 pts (20% of score)

20D Institutional Volume Accumulation (±1.8% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit14/20 pts (-6 pt drag)

Macro rate sensitivity & RSI-14 (52.3) create a -6 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
68
Grade B-$99.99+0.1% Next Q
Q2 (-2Q)
71
Grade B$100.10+0.2% Next Q
Q3 (-1Q)
73
Grade B$100.32+0% Next Q
Current
76
Grade B+$100.31+7.6% Hist 90D α
Trajectory: B- (68) → B+ (76)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LNTH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 76/100 (B+) score, LNTH faces multiple-compression risk if 28.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 58.6% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($100.24) or 200D SMA ($92.08) invalidates the momentum regime and cuts Target Base ($108.44) toward Bear Floor ($82.25).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LNTH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LNTH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 76%NO 24%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why LNTH Stock slipped -0.15% Today — RQD Quant Desk Flash

Lantheus Holdings Inc. (LNTH) slipped -0.15% to $100.31, trading at 81% of its 52-week range ($50.15 – $111.86). High-quality cash engine (61.1% gross margin, 20% return on capital) with steady institutional support.

  • ▸Technical Tape: Trading at 81% of its 52-week range ($50.15 – $111.86) with RSI-14 at 52.3 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±1.8% around $100.31 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable B+ (Buy) backed by 61.1% gross margin and $320.8M annual free cash flow.
Live LNTH Headlines & Catalysts
MARKET WIREZacks Investment Research • 2d ago
Should I buy Lantheus (LNTH)

Zacks Investment Research report covering Lantheus Holdings Inc. (LNTH) market action, institutional positioning, and fundamental catalysts.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LNTH Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LNTH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +16.88%⚡ TESTING RESISTANCE
2026-11-04O $100.5H $100.5L $100.3C $100.3VOL 931.9K
RES: $100.4SUP: $99.80SMA50: $100.2SMA200: $92.08
$115.1$101.6$88.07$74.54$61.01RES $100.4SUP $99.80$100.32026-05-052026-06-222026-08-062026-09-222026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LNTH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LNTH Butterfly Map → + Track LNTH →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
21.4%/yr Implied 5Y Growth

vs. +0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LNTH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LNTH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LNTH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LNTH)

Health Care Rank #29 of 1015 ⚔️ ORKA vs LNTH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LNTH vs. ORKA, NEOG, CLDX, NTLA)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Lantheus Holdings Inc. (LNTH) ranks #29 by composite RQD confidence (76/100, grade B+) and #136 by equity capitalization ($6.55B). Within this direct 5-issuer industry benchmark cohort, LNTH leads on earnings valuation at 28.0x trailing P/E, while LNTH leads on capital efficiency and profitability with 20.3% ROIC and 61.1% gross margin. LNTH currently leads its immediate peer cohort in composite quantitative strength at 76/100 (B+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LNTH ACTIVE
Lantheus Holdings Inc.
B+ 76/100 28.0x 61.1% 20.3% -0.15% $6.55B Benchmark Subject
ORKA
Oruka Therapeutics Inc.
D+ 53/100 — — -18.8% -1.49% $6.32B /orka-vs-lnth →
NEOG
Neogen Corporation
D 47/100 — 46.9% -0.6% 0.00% $2.58B /neog-vs-lnth →
CLDX
Celldex Therapeutics Inc.
E 29/100 — 87.1% -35.0% -3.52% $2.28B /cldx-vs-lnth →
NTLA
Intellia Therapeutics Inc.
E 25/100 — — -35.0% -6.50% $1.63B /ntla-vs-lnth →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001521036 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lantheus Holdings Inc. (LNTH) reported GAAP revenue of $1.54B (+0.5% vs. FY2024 revenue of $1.53B , and +18.9% cumulative change since FY2023) , GAAP net income of $233.6M, operating cash flow of $390.1M, and free cash flow of $320.8M (-32.6% YoY). On the balance sheet, LNTH closed FY2025 with $2.23B in total assets against $511.9M in total debt (Altman Z-Score: 5.34, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.54B $233.6M $390.1M $320.8M $2.23B $511.9M
FY2024 (FY) 2024-12-31 $1.53B $312.4M $544.8M $475.7M $1.98B $401.5M
FY2023 (FY) 2023-12-31 $1.30B $326.7M $305.3M $246.9M $3.60B $842.7M

3. LNTH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LNTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Lantheus Holdings Inc. (NASDAQ: LNTH) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $100.31 (-0.15% 1D, market cap $6.55B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, LNTH ranks #29 in composite RQD confidence.

How does LNTH compare to ORKA and NEOG in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), LNTH carries a Roarable B+ (76/100 RQD), trailing P/E of 28.0x, gross margin of 61.1%, and ROIC of 20.3%. By comparison, ORKA (Oruka Therapeutics Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -18.8%, cap $6.32B) and NEOG (Neogen Corporation) posts a D grade (47/100 RQD, P/E N/A, ROIC -0.6%, cap $2.58B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LNTH?

Per LNTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001521036), Lantheus Holdings Inc. generated $1.54B in revenue (+0.5% YoY), $233.6M in net income, and $320.8M in free cash flow against $2.23B in total assets and $511.9M in total debt. Key quantitative strengths: Strong cash generator (61.1% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LNTH trading relative to its 50-day, 200-day, and 52-week technical levels?

LNTH last traded at $100.31 (-0.15% on volume of 931,882 shares), positioning the stock +0.07% above its 50-day simple moving average ($100.24) and +8.94% above its 200-day simple moving average ($92.08). Across its 52-week range of $50.15 to $111.86, LNTH sits at the 81.3% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of ±1.8% ($98.50 to $102.12).

Direct Sub-Reports: LNTH RQD Cockpit LNTH 12M Forecast LNTH Earnings & Move LNTH Dividends & DRIP LNTH Insiders & 13F LNTH Whale Options LNTH Profit Sankey LNTH News & Why
ROARABLE RATING BRIEF • RQD 76/100 (B+) ✓ SEC XBRL & RQD VERIFIED

LNTH — Lantheus Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Lantheus Holdings Inc. (LNTH) earns a live Roarable RQD composite score of 76/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $100.31 (-0.15% 1D, market capitalization $6.55B).

  • Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 20.3%, gross margin of 61.1%, operating margin of 20.2%, and free cash flow yield of 4.90%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (15/20): Incorporates a 0.88x equity beta, Altman Z-Score of 5.34, Piotroski F-Score of 7/9, and Debt/Equity of 0.44x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Lantheus Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry..5B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lantheus Holdings Inc. (LNTH) reported $1.54B in annual revenue (up from $1.53B in FY2024, +0.5% YoY) and $233.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.30B revenue, $326.7M net income) through FY2025, LNTH scaled operating cash flow to $390.1M and free cash flow to $320.8M, backed by $2.23B in total assets against $511.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B+ • RQD 76/100): Strong cash generator (61.1% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $50.15 – $111.86 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 28.0x trailing P/E and 18.0x EV/EBITDA against 20.2% operating margins and a 0.88x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), LNTH carries a macro regime beta of 0.88 and gross margin of 61.1%.

  • Key Question #1: Can LNTH sustain or expand its 20.2% operating margin and 20.3% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.54B and free cash flow of $320.8M, how will capital allocation balance growth reinvestment against $511.9M in total debt?
  • Key Question #3: How sensitive is LNTH's 26.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.88x)?

LNTH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lantheus Holdings Inc. (LNTH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LNTH Debate Forum (3) ↓
🟡 MARKET WIRE Zacks Investment Research • 2d ago
Should I buy Lantheus (LNTH)

Zacks Investment Research report covering Lantheus Holdings Inc. (LNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LNTH Bull vs. Bear Conversation Board — What's Your Call at $100.31?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LNTH 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LNTH:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $130.60 (+30.0%)
📌 Pinned Debate

A 20.3% ROIC, a 5.34 Altman Z-Score, and a 0.44 Debt/Equity ratio point to a high-return, low-leverage business.

Here is why I am bullish on LNTH here at $100.46: A 20.3% ROIC, a 5.34 Altman Z-Score, and a 0.44 Debt/Equity ratio point to a high-return, low-leverage business.. Compare LNTH's 20.2% operating margin and 20.3% ROIC against the rest of Biotechnology: In Vitro & In Vivo Diagnostic Substances. As long as cash conversion holds up, dips toward $95.44 are getting bought.

VolSurface_Trader 🐂 BULL

@RedlineAuditor Shorting a 15/20 institutional whale-flow stock at $100.46 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $79.36 (-21.0%)
Spot @ $100.46

Revenue grew from $1.30B to $1.54B while net income fell from $326.7M to $233.6M and cash dropped from $912.8M to $359.1M.

Revenue grew from $1.30B to $1.54B while net income fell from $326.7M to $233.6M and cash dropped from $912.8M to $359.1M.. Look at the math on LNTH: paying 28.0x trailing P/E for 20.3% ROIC and 20.2% operating margins leaves zero margin of safety if Biotechnology: In Vitro & In Vivo Diagnostic Substances demand softens. I'd wait for a retest of $88.40 before getting long.

LIVE TAPE